<description>&lt;p&gt;In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training. &lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Full episode for Barbell Medicine Plus subscribers at &lt;span&gt;https://barbellmedicine.supercast.com/&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;h2&gt;&lt;span&gt;Timestamps:&lt;/span&gt;&lt;/h2&gt;&lt;p&gt;&lt;strong&gt;0:00&lt;/strong&gt; — Introduction&lt;/p&gt;&lt;p&gt;&lt;strong&gt;3:26&lt;/strong&gt; — VO2 Max vs. Cardiorespiratory Fitness for Longevity&lt;/p&gt;&lt;p&gt;&lt;strong&gt;14:11&lt;/strong&gt; — GLP-1 Costs: What you should actually be paying now&lt;/p&gt;&lt;p&gt;&lt;strong&gt;21:43&lt;/strong&gt; — Is Walking Enough for Cardiovascular Health?&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;h2&gt;Next Steps:&lt;/h2&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;For evidence-based resistance training programs: barbellmedicine.com/training-programs&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;For individualized training consultation: barbellmedicine.com/coaching&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Explore our full library of articles on health and performance: barbellmedicine.com/resources&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;h2&gt;Resources: &lt;/h2&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;JAMA Network Open — Cardiorespiratory Fitness &amp;amp; Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode  https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428&lt;/li&gt;&lt;li&gt;JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women  https://jamanetwork.com/journals/jama/fullarticle/379243&lt;/li&gt;&lt;li&gt;Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets  https://www.barbellmedicine.com/vital-5-action-plan/&lt;/li&gt;&lt;li&gt;Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month)  https://www.lillydirect.com/zepbound&lt;/li&gt;&lt;li&gt;NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month)  https://www.novocare.com/patient/medicines/wegovy.html&lt;/li&gt;&lt;li&gt;Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval)  https://www.lilly.com/news/stories/what-to-know-about-orforglipron&lt;/li&gt;&lt;/ul&gt;&lt;br/&gt;&lt;br/&gt;Advertising Inquiries: &lt;a href='https://redcircle.com/brands'&gt;https://redcircle.com/brands&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;Privacy &amp; Opt-Out: &lt;a href='https://redcircle.com/privacy'&gt;https://redcircle.com/privacy&lt;/a&gt;</description>

Barbell Medicine Podcast

Barbell Medicine

Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)

MAR 24, 202630 MIN
Barbell Medicine Podcast

Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)

MAR 24, 202630 MIN

Description

In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training. Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/Timestamps:0:00 — Introduction3:26 — VO2 Max vs. Cardiorespiratory Fitness for Longevity14:11 — GLP-1 Costs: What you should actually be paying now21:43 — Is Walking Enough for Cardiovascular Health?Next Steps:For evidence-based resistance training programs: barbellmedicine.com/training-programsFor individualized training consultation: barbellmedicine.com/coachingExplore our full library of articles on health and performance: barbellmedicine.com/resourcesTo consult with Drs. Baraki or Feigenbaum email us at [email protected]: JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepboundNovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.htmlOrforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipronAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy